About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Teijin Ltd. et al. v. Macleods Pharmaceuticals Ltd. et al.
1:15-cv-00454; filed June 4, 2015 in the District Court of Delaware
• Plaintiffs: Teijin Ltd.; Teijin Pharma Ltd.; Takeda Pharmaceuticals U.S.A., Inc.
• Defendants: Macleods Pharmaceuticals Ltd.; Macleods Pharma USA, Inc.
Infringement of U.S. Patent No. 7,361,676 ("Solid Preparation Containing Single Crystal Form," issued April 22, 2008) following a Paragraph IV certification as part of Macleods' filing of an ANDA to manufacture a generic version of Takeda's Uloric® (febuxostat, used for the chronic management of hyperuricemia in patients with gout). View the complaint here.
Takeda Pharmaceutical Co. Ltd. et al. v. Actavis Laboratories FL, Inc. et al.
1:15-cv-00451; filed June 3, 2015 in the District Court of Delaware
• Plaintiffs: Takeda Pharmaceutical Co. Ltd.; Takeda Pharmaceuticals International GmbH; Takeda Pharmaceuticals USA, Inc.; Takeda Pharmaceuticals America, Inc.; Orexigen Therapeutics, Inc.
• Defendants: Actavis Laboratories FL, Inc.; Actavis Pharma, Inc.; Andrx Corp.; Actavis, Inc.
Infringement of U.S. Patent Nos. 7,375,111 ("Compositions for Affecting Weight Loss," issued May 20, 2008), 7,462,626 (same title, issued December 9, 2008), 8,088,786 ("Layered Pharmaceutical Formulations," issued January 3, 2012), 8,318,788 (same title, issued November 27, 2012), 8,722,085 ("Methods for Administering Weight Loss Medications," issued May 13, 2014), 8,815,889 ("Composition and Methods for Increasing Insulin Sensitivity," issued August 26, 2014), and 8,916,195 ("Sustained Release Formulation of Naltrexone," issued December 23, 2014) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Takeda's Contrave® (naltrexone hydrochloride and bupropion hydrochloride, used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of (1) 30 kg/m2 or greater (obese), or (2) 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity). View the complaint here.
Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc.
2:15-cv-03684; filed June 1, 2015 in the District Court of New Jersey
Infringement of U.S. Patent No. 8,952,062 ("Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy," issued February 10, 2015) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Jazz's Xyrem® (sodium oxybate, used to treat narcolepsy). View the complaint here.
